Beyond Air® To Participate in the Truist Securities BioPharma Symposium
GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a…
Pharmaceuticals, Biotechnology and Life Sciences
GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a…
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…
— Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment — —…
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently…
– Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code…
HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Predicine, a pioneer in the liquid biopsy, announce its participation in the…
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival…
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company…
Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S.…